For example, in NGR-GY004 study, the median PFS of PARPi monotherapy for platinum-sensitive recurrent ovarian cancer patients with BRCA1/2 mutations was better than platinum-based chemotherapy, and the ongoing OPAL-C trial (NCT03574779) is exploring the superiority of PARPi monotherapy compared to Platinum-Taxane in neoadjuvant chemotherapy for patients with homologous recombination deficiency (HRD)-positive tumors, however, these studies have not yet published the results of overall survival. The gene discussed is BRCA1; the disease is ovarian cancer.